Immunome OverviewImmunome EBIT
EBIT (Earnings Before Interest and Taxes) analysis for IMNM.
Quarterly EBIT
-$59.33M
↓ 32.92% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$228.81M
↓ 19.94% YoY
Trailing 12 months ending Mar 31, 2026
Immunome OverviewEBIT (Earnings Before Interest and Taxes) analysis for IMNM.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026